MULTIFACTORIAL ANALYSIS OF THE PROGNOSIS OF NONANAPLASTIC N2 OPERATED LUNG CANCERS

被引:0
|
作者
ROESLIN, N
WARTER, A
GASSER, B
CHAKFE, N
WEIL, G
DUMONT, P
WIHLM, JM
MORAND, G
WITZ, JP
机构
来源
ANNALES DE CHIRURGIE | 1991年 / 45卷 / 08期
关键词
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
The marked disparity of the published 5-year survival rates (0 to 3 %) for non-anaplastic, operated N2 lung cancers would suggest the marked heterogeneity of the patients studied. We prospectively studies 97 N2 tumours for which << curative >> resection was performed between 1983 and 1986. The overall survival rate was 28% at 3 years, 19% at 4 years and 12% at 5 years. Survival was studied on the basis of several parameters concerning the tumour: histological type and degree of differentiation, T (TNM), modality of invasion (circumscribed, infiltrating), the quality of the stroma (absent, fibrotic, cellular), the mitotic index, the necrosis rate, presence or absence of microscopic invasion of blood vessels; and concerning the nodes : site, number (solitary, multiple), size of the metastasis (massive, microscopic), macroscopic or microscopic invasion of the capsule. We know the outcome for all of our patients: 81 have died and 16 are still alive. Sixty-one have developed metastases, 5 have developed local and regional recurrences and 3 have both a recurrence and metastases. Univariate analysis demonstrated that a small number of parameters significantly influence survival: microscopic invasion of blood vessel (chi-2 = 5.24, p < 0.02), macroscopic and microscopic invasion of the lymph node capsule. In order to more clearly define the prognostic factors, we used Cox's multidimensional model. This model was applied to the three significant parameters to which we added two other variables which non-significantly tended to be related to survival: tumour necrosis and number of lymph nodes involved. This analysis showed that the prognostic information can be sumarised by a single factor: microscopic invasion of blood vessels; the other factors are contingent or redundant. This analysis also demonstrated that the best theoretical 5-year survival rate which wa can hope to obtain for this group of patients is 26%. Is strict selection leading to good numerical results justified in a disease whose intimate mechanisms of progression are unknown and in which surgery, although unreliable, remains the only chance of cure?
引用
收藏
页码:673 / 678
页数:6
相关论文
共 50 条
  • [31] THE UTILITY OF FDG-PET/CT FOLLOWING RADIOCHEMOTHERAPY IN N2 H&N CANCERS
    Prewett, S.
    Loo, S.
    Beadsmoore, C.
    Geropantas, K.
    Martin, C.
    Rogues, T.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S333 - S334
  • [32] Analysis of asbestos bodies and nude fibres in the lung parenchyma of operated lung cancers. A retrospective monocentric study of 73 cases
    Vincent, M.
    Perrin, G.
    Vuillermoz-Blas, S.
    Laennec, E.
    Blanchet, A. -S.
    Frecon, G.
    Thivolet, F.
    Roux, E.
    Chemarin, C.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2011, 67 (05) : 298 - 303
  • [33] Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
    Lakhani, SR
    Jacquemier, J
    Sloane, JP
    Gusterson, BA
    Anderson, TJ
    van de Vijver, MJ
    Farid, LM
    Venter, D
    Antoniou, A
    Storfer-Isser, A
    Smyth, E
    Steel, CM
    Haites, N
    Scott, RJ
    Goldgar, D
    Neuhausen, S
    Daly, PA
    Ormiston, W
    McManus, R
    Scherneck, S
    Ponder, BAJ
    Ford, D
    Peto, J
    Stoppa-Lyonnet, D
    Bignon, YJ
    Struewing, JP
    Spurr, NK
    Bishop, DT
    Klijn, JGM
    Devilee, P
    Cornelisse, CJ
    Lasset, C
    Lenoir, G
    Barkardottir, RB
    Egilsson, V
    Hamann, U
    Chang-Claude, J
    Sobol, H
    Weber, B
    Stratton, MR
    Easton, DF
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (15): : 1138 - 1145
  • [34] Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
    Brown, DL
    Cole, BF
    Arrick, BA
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (01) : 90 - 91
  • [35] Where is the boundary between N1 and N2 stations in lung cancer?
    Asamura, H
    Suzuki, K
    Kondo, H
    Tsuchiya, R
    ANNALS OF THORACIC SURGERY, 2000, 70 (06): : 1839 - 1845
  • [36] Concurrent radio-chemotherapy in N2 non small cell lung cancer: interim analysis
    Granone, P
    Margaritora, S
    Cesario, A
    Bonatti, P
    Galetta, D
    Picciocchi, A
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1997, 12 (03) : 366 - 371
  • [37] Analysis of solubility on N2 in liquid CO2
    Yang W.
    Li S.
    Feng Y.
    Shan G.
    Zhang X.
    Dongnan Daxue Xuebao (Ziran Kexue Ban)/Journal of Southeast University (Natural Science Edition), 2016, 46 (04): : 776 - 781
  • [38] The evolution of therapy for patients with stage IIIA (N2) lung cancer
    Harpole, DH
    CHEST, 1997, 112 (04) : S201 - S202
  • [39] Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum
    Carter, Lily
    Apte, Vedika
    Shukla, Arushi
    Ghose, Aruni
    Mamidi, Raj
    Petohazi, Alexandra
    Makker, Shania
    Banerjee, Soirindhri
    Boussios, Stergios
    Banna, Giuseppe L.
    CURRENT ONCOLOGY REPORTS, 2024, 26 (01) : 65 - 79
  • [40] Outcomes of pneumonectomy for N2 non small cell lung cancer
    Guinard, Sophie
    Olland, Anne
    Puyraveau, Marc
    Seitlinger, Joseph
    Falcoz, Pierre Emmanuel
    Massard, Gilbert
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54